DCT

1:26-cv-00870

Adverio Pharma GmbH v. Zenara Pharma Pvt Ltd

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:26-cv-00870, D. Del., 07/16/2026
  • Venue Allegations: Venue is asserted as proper in the District of Delaware because the defendant, a foreign corporation, is subject to personal jurisdiction in the district and has previously consented to jurisdiction in the district in other patent litigation matters.
  • Core Dispute: Plaintiffs allege that Defendant's submission of an Abbreviated New Drug Application (ANDA) to market a generic version of the pulmonary hypertension drug ADEMPAS® (riociguat) constitutes an act of infringement of a patent covering a specific crystalline form of the active ingredient.
  • Technical Context: The technology concerns pharmaceutical polymorphism, specifically the identification and characterization of distinct crystalline forms of the active pharmaceutical ingredient riociguat, which are critical for ensuring drug product stability, quality, and bioavailability.
  • Key Procedural History: The lawsuit is a Hatch-Waxman action initiated under 35 U.S.C. § 271(e)(2) following Defendant's notification to Plaintiffs, via a letter dated June 1, 2026, of its ANDA submission containing a Paragraph IV certification against the patent-in-suit.

Case Timeline

Date Event
2013-02-21 Earliest Priority Date for U.S. Patent No. 12,503,469
2025-12-23 U.S. Patent No. 12,503,469 Issued
2026-06-01 Date of Defendant's Paragraph IV Notice Letter to Plaintiffs
2026-07-16 Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 12,503,469 - Forms of Methyl {4,6-Diamino-2-[1-(2-Fluorobenzyl)-1H-Pyrazolo[3-4-B]Pyridino-3-Yl] Pyrimidino-5-Yl} Methyl Carbamate

  • Shorthand: "the '469 Patent"
  • Issued: December 23, 2025

The Invention Explained

  • Problem Addressed: The patent's background section implies that prior art methods for synthesizing the active pharmaceutical ingredient riociguat resulted in a crude product that required extensive purification, and the specific solid-state forms of the compound were not well understood or controlled '469 Patent, col. 2:54-63 '469 Patent, col. 3:1-3
  • The Patented Solution: The invention identifies and characterizes several distinct solid-state forms (polymorphs and solvates) of riociguat, including a thermodynamically stable anhydrous form designated "Modification I" '469 Patent, abstract '469 Patent, col. 5:15-24 The patent provides specific analytical data, such as X-ray powder diffraction (XRPD) peak positions, to precisely define and distinguish Modification I from other forms '469 Patent, col. 7:39-44
  • Technical Importance: Controlling the crystalline form of an active pharmaceutical ingredient is essential for ensuring lot-to-lot consistency in manufacturing, as well as predictable stability and bioavailability of the final drug product '469 Patent, col. 5:26-33

Key Claims at a Glance

  • The complaint asserts infringement of at least independent claim 5 '469 Patent, col. 28:1-18
  • The essential elements of independent claim 5 are:
    • A method for the treatment of pulmonary hypertension associated with thromboembolism (CTEPH).
    • Comprising administering a composition that includes a therapeutically effective amount of the compound of formula (I) (riociguat) and a pharmaceutically acceptable carrier.
    • Wherein more than 90 percent by weight of the compound of formula (I) in the composition is in the crystalline form of Modification I.
    • Wherein the compound of formula (I) in the form of Modification I has an X-Ray powder diffractogram comprising peak maxima of the 2 Theta angle of 6.7, 9.1, and 17.8.
  • The complaint alleges infringement of "each of the '469 patent" and reserves the right to assert other claims '469 Patent, ¶34

III. The Accused Instrumentality

Product Identification

The accused instrumentalities are Zenara's generic riociguat tablets in 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg, and 2.5 mg dosage strengths, for which Zenara submitted ANDA No. 221423 to the FDA '469 Patent, ¶8

Functionality and Market Context

The accused products are generic versions of Plaintiffs' ADEMPAS® tablets and are intended to be therapeutic equivalents for the same medical indications '469 Patent, ¶23 The complaint alleges that these products contain the active ingredient riociguat in the form of "Modification I" '469 Patent, ¶27 The complaint provides a chemical structure diagram identifying the active compound, riociguat '469 Patent, ¶19 Zenara seeks to engage in the commercial manufacture and sale of these generic products in the United States prior to the expiration of the '469 Patent '469 Patent, ¶1

IV. Analysis of Infringement Allegations

'469 Patent Infringement Allegations

Claim Element (from Independent Claim 5) Alleged Infringing Functionality Complaint Citation Patent Citation
A method for the treatment of pulmonary hypertension associated with thromboembolism (CTEPH) Defendant's proposed product labeling will direct and instruct users to administer its generic riociguat tablets for the treatment of CTEPH. ¶19; ¶28 col. 28:1-4
comprising administering a composition comprising a therapeutically effective amount of a compound of the formula (I)... and a pharmaceutically acceptable carrier Defendant's ANDA Products are tablets containing riociguat, the compound of formula (I), which Defendant intends to manufacture, use, and sell upon FDA approval. ¶26; ¶28 col. 28:4-7
in which more than 90 percent by weight relative to the total weight of all forms of the compound of formula (I) in the composition is in the crystalline form of Modification I The complaint alleges that Defendant's ANDA Products meet all limitations of at least claim 5, which includes the purity requirement relative to Modification I. ¶28 col. 28:7-12
to a patient in need thereof, wherein the compound of the formula (I) has an X-Ray powder diffractogram comprising peak maxima of the 2 Theta angle of 6.7, 9.1 and 17.8. The complaint alleges Defendant's ANDA Products contain riociguat in the form of Modification I, and further states it is Defendant's position that this form exhibits the recited X-ray diffraction peaks. ¶27 col. 28:12-18

Identified Points of Contention

  • Scope Questions: A central issue may be whether the crystalline form in Zenara's product is the same as the claimed "Modification I." The complaint alleges Zenara does not contest meeting claim limitations "other than the limitation related to the X-ray diffraction peaks," but in the next sentence states it is Zenara's position that its product does exhibit those peaks '469 Patent, ¶27 This suggests a potential dispute over the precise interpretation of the XRPD data or the full scope of what constitutes "Modification I" as defined by the patent.
  • Technical Questions: The complaint asserts that Zenara's product meets the "more than 90 percent" purity limitation for Modification I '469 Patent, ¶28, but, as is typical for an initial pleading, it does not present the underlying analytical data from Zenara's ANDA. A key factual question will be what Zenara's manufacturing data and quality control specifications show regarding the polymorphic identity and purity of its final drug product.

V. Key Claim Terms for Construction

  • The Term: "Modification I"
  • Context and Importance: The definition of "Modification I" is fundamental to the infringement analysis. The case will depend on whether the crystalline form in Zenara's product falls within the patent's definition of this specific polymorph.
  • Intrinsic Evidence for Interpretation:
    • Evidence for a Broader Interpretation: A party arguing for a broader scope may point to the language of claim 5 itself, which defines Modification I by the presence of only three specific XRPD peaks at 2-theta angles of 6.7, 9.1, and 17.8 '469 Patent, col. 28:15-18 This could support an argument that any form exhibiting these three peaks infringes, regardless of other characteristics.
    • Evidence for a Narrower Interpretation: A party arguing for a narrower scope may cite the specification, which states that Modification I "can be characterized unambiguously by a X-Ray powder diffractogram comprising peak maxima" at a much longer list of eleven 2-theta angles '469 Patent, col. 7:39-44 This party could argue that to be "Modification I," a sample must match this more complete "fingerprint," not just the three peaks recited in the claim.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges that Defendant will actively induce infringement by providing a product label that instructs medical professionals and patients to use the generic product in a manner that directly infringes the method claims of the '469 Patent '469 Patent, ¶32
  • Willful Infringement: The complaint alleges that Defendant has knowledge of the '469 Patent, at least as of its Paragraph IV certification, and has continued to assert its intent to market its product before the patent's expiration '469 Patent, ¶31 Plaintiffs seek a declaration that the case is "exceptional" and an award of attorneys' fees, which is consistent with a claim for willful infringement '469 Patent, Prayer ¶(e)

VII. Analyst's Conclusion: Key Questions for the Case

  • A core issue will be one of definitional scope: Is the term "Modification I" defined solely by the three X-ray diffraction peaks recited in claim 5, or must an accused product exhibit the more extensive set of characterization data described in the patent's specification to fall within the claim's scope?
  • A key evidentiary question will be one of factual identity and purity: Assuming a construction of "Modification I" is established, does the evidence from Defendant's ANDA and any subsequent testing demonstrate that its manufactured drug product will, in fact, contain "more than 90 percent" of the active ingredient as that specific crystalline form?
Loading Complaint